367 related articles for article (PubMed ID: 27116720)
1. Parenteral Treatment of Multiple Sclerosis: The Advent of Monoclonal Antibodies.
Singer BA
Semin Neurol; 2016 Apr; 36(2):140-7. PubMed ID: 27116720
[TBL] [Abstract][Full Text] [Related]
2. [Monoclonal antibodies for the treatment of multiple sclerosis].
Sánchez-Seco VG; Casanova Peño I; Arroyo González R
Med Clin (Barc); 2014 Dec; 143 Suppl 3():30-4. PubMed ID: 25732947
[TBL] [Abstract][Full Text] [Related]
3. [Biological treatment of multiple sclerosis].
Sørensen PS; Sellebjerg F
Ugeskr Laeger; 2008 Jun; 170(24):2156-9. PubMed ID: 18565303
[TBL] [Abstract][Full Text] [Related]
4. Novel Agents for Relapsing Forms of Multiple Sclerosis.
Straus Farber R; Harel A; Lublin F
Annu Rev Med; 2016; 67():309-21. PubMed ID: 26394285
[TBL] [Abstract][Full Text] [Related]
5. Monoclonal antibodies in the treatment of multiple sclerosis.
Di Pauli F; Berger T; Reindl M
Curr Med Chem; 2009; 16(36):4858-68. PubMed ID: 19929782
[TBL] [Abstract][Full Text] [Related]
6. Monoclonal antibodies in treatment of multiple sclerosis.
Rommer PS; Dudesek A; Stüve O; Zettl UK
Clin Exp Immunol; 2014 Mar; 175(3):373-84. PubMed ID: 24001305
[TBL] [Abstract][Full Text] [Related]
7. Update on disease-modifying treatments for multiple sclerosis.
Carrithers MD
Clin Ther; 2014 Dec; 36(12):1938-1945. PubMed ID: 25218310
[TBL] [Abstract][Full Text] [Related]
8. New biological agents in the treatment of multiple sclerosis.
Buc M
Bratisl Lek Listy; 2018; 119(4):191-197. PubMed ID: 29663814
[TBL] [Abstract][Full Text] [Related]
9. Specific immune intervention with monoclonal antibodies for the treatment of multiple sclerosis.
Trebst C; Voss E; Skripuletz T; Stangel M
Curr Med Chem; 2010; 17(7):640-50. PubMed ID: 20088763
[TBL] [Abstract][Full Text] [Related]
10. Monoclonal antibody treatments for multiple sclerosis.
Rose JW; Foley J; Carlson N
Curr Neurol Neurosci Rep; 2008 Sep; 8(5):419-26. PubMed ID: 18713579
[TBL] [Abstract][Full Text] [Related]
11. [Current treatment of multiple sclerosis].
Gout O; Bensa C; Assouad R
Rev Med Interne; 2010 Aug; 31(8):575-80. PubMed ID: 20579785
[TBL] [Abstract][Full Text] [Related]
12. Update on disease-modifying therapies for multiple sclerosis.
Vargas DL; Tyor WR
J Investig Med; 2017 Jun; 65(5):883-891. PubMed ID: 28130412
[TBL] [Abstract][Full Text] [Related]
13. [Highly active multiple sclerosis: options for monoclonal antibody therapy].
Khachanova NV
Zh Nevrol Psikhiatr Im S S Korsakova; 2019; 119(10. Vyp. 2):49-57. PubMed ID: 31934988
[TBL] [Abstract][Full Text] [Related]
14. Recent developments in multiple sclerosis therapeutics.
Spain RI; Cameron MH; Bourdette D
BMC Med; 2009 Dec; 7():74. PubMed ID: 19968863
[TBL] [Abstract][Full Text] [Related]
15. [Immunosuppression with monoclonal antibodies in multiple sclerosis].
Vermersch P; Zéphir H
Rev Neurol (Paris); 2007 Jun; 163(6-7):682-7. PubMed ID: 17607190
[TBL] [Abstract][Full Text] [Related]
16. Mechanisms of action for treatments in multiple sclerosis: Does a heterogeneous disease demand a multi-targeted therapeutic approach?
Chofflon M
BioDrugs; 2005; 19(5):299-308. PubMed ID: 16207071
[TBL] [Abstract][Full Text] [Related]
17. Established and novel disease-modifying treatments in multiple sclerosis.
Cross AH; Naismith RT
J Intern Med; 2014 Apr; 275(4):350-63. PubMed ID: 24444048
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of monoclonal antibody therapies for relapsing remitting multiple sclerosis: A network meta-analysis.
Xu X; Chi S; Wang Q; Li C; Xu B; Zhang J; Chen X
Mult Scler Relat Disord; 2018 Oct; 25():322-328. PubMed ID: 30195200
[TBL] [Abstract][Full Text] [Related]
19. Current and future disease-modifying therapies in multiple sclerosis.
Lim SY; Constantinescu CS
Int J Clin Pract; 2010 Apr; 64(5):637-50. PubMed ID: 20456216
[TBL] [Abstract][Full Text] [Related]
20. Treating multiple sclerosis with natalizumab.
Iaffaldano P; Lucchese G; Trojano M
Expert Rev Neurother; 2011 Dec; 11(12):1683-92. PubMed ID: 22091593
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
